Copyright © Inderes 2011 - present. All rights reserved.

Orion

67.47 EUR

+0.85 %

14,340 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

+0.85 %
-0.71 %
+6.00 %
+6.17 %
+5.84 %
+23.75 %
+62.15 %
+98.91 %
+500.80 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
9.52B EUR
Turnover
2.18M EUR
P/E (adj.) (26e)
18.89
EV/EBIT (adj.) (26e)
14.69
P/B (26e)
6.16
EV/S (26e)
4.87
Dividend yield-% (26e)
2.64 %
Coverage
Recommendation
Accumulate
Target price
75.00 EUR
Updated
12.02.2026
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 13.02.2026

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
23.4
2026

Interim report Q1'26

17.7
2026

Interim report Q2'26

19.10
2026

Half year dividend

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
And then potentially destroy Orion’s shareholder value in the process. As an Orion shareholder (I don’t own Faron), I do not support such a scenario at all. Deals can be made for interesting drug candidates, if there is potential. On the other hand, if Faron’s performance continues...
2/16/2026, 5:45 PM
by L Dabio
16
Turku-based Thestra finds a partner in Orion to support its unique invention Despite decades of research, there have been no targeted treatments for head and neck cancer. A medical startup has invented a method that ensures an accurate diagnosis of the cancer. ts.fi – 17 Feb 26 Turkulainen...
2/18/2026, 8:28 AM
by Dissidentti
12
Here are Antti’s comments on an unsurprising Q4 Orion’s Q4 report and the full financial year were strong, even though the end of the year fell slightly short of market expectations. The quarter was characterized by a 180 MEUR milestone payment, adjusted for which the result improved...
2/13/2026, 6:13 AM
by Sijoittaja-alokas
9
And here is the result itself: cdn.prod.nntech.io report.pdf 1872.33 KB Highlights: October-December 2025: Net sales totalled EUR 695.3 (October–December 2024: 434.4) million • Operating profit was EUR 328.1 (92.7) million • Basic earnings per share were EUR 1.85 (0.52) • Cash flow...
2/12/2026, 11:08 AM
by Sierain
9
Considering the precarious situation Faron has found itself in, perhaps the possibility of merging it with Orion should be seriously explored. Although Orion might not yet be considered a true Big Pharma (BP) company, a merger with Faron would not be an overwhelming risk for it. ...
2/16/2026, 2:35 PM
by Tero Vierros
8
https://www.marketscreener.com/news/danske-bank-upgrades-orion-to-buy-hold-sets-price-target-at-75-euros-bn-ce7e5fdede8af721
3/10/2026, 9:16 AM
by Dissidentti
7
Interesting information, the collaboration between Thestra and Orion. The target cancer is a very distressing disease; HNSCC causes great suffering. Head and neck squamous cell carcinoma (HNSCC) can form in the squamous epithelial layers of the oral cavity, larynx, nasopharynx, and...
2/18/2026, 10:18 AM
by veronmaksaja
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.